Kidney cancer treatment before surgery
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with clear cell renal cell carcinoma, a type of kidney cancer.
- Your cancer is considered intermediate-high risk, high risk, or has spread to certain nearby areas or soft tissue.
- You are scheduled to have surgery to remove the kidney tumor.
- You are at least 18 years old.
- You are in generally good health (able to care for yourself), with no serious heart or lung problems.
- You have not had previous chemotherapy or radiation for your kidney cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving two immunotherapy drugs before surgery can safely shrink kidney cancer tumors and help your body fight the cancer. You would receive the drugs before your scheduled surgery, and then your cancer would be removed as planned.
This trial tests whether giving an immunotherapy drug (PD-L1 inhibitor) and an oral medication (anlotinib) before surgery can help shrink complex kidney tumors so that surgeons can remove only part of the kidney, preserving more kidney function. It may help you avoid losing your whole kidney.
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
This trial tests if taking two drugs, belzutifan and pembrolizumab, before surgery can help shrink high-risk kidney cancer tumors and improve outcomes. It may be an option for people with locally advanced clear cell kidney cancer who are scheduled for nephrectomy.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.